Based primarily on clinical trials
led by Arjun V. Balar, MD, assistant professor of medicine and director of the Genitourinary Medical Oncology Program, the FDA approved atezolizumab (Tecentriq ®) and pembrolizumab (Keytruda ®) as first - line treatments
for these particularly frail patients with advanced
bladder cancer in early 2017.
Discovering genetic and environmental risk factors
for bladder cancer in dogsAbstract: Bladder cancer (transitional cell carcinoma, TCC) accounts for up to 2 % of all canine cancers, and often leads to euth
bladder cancer in dogsAbstract:
Bladder cancer (transitional cell carcinoma, TCC) accounts for up to 2 % of all canine cancers, and often leads to euth
Bladder cancer (transitional cell carcinoma, TCC) accounts
for up to 2 % of all canine
cancers, and often
leads to euthanasia.